|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1819202122232425262728...4041» |
- | dalfampridine / Generic mfg.
New P4 trial: RETRAP: Resistance Training and Amino Pyridine in Multiple Sclerosis (clinicaltrials.gov) - May 18, 2014
P4, N=50, Recruiting, Sponsor: University of Southern Denmark
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P2 trial: SIMPLIFY: Natalizumab Subcutaneous Immunogenicity and Safety Study (clinicaltrials.gov) - May 18, 2014
P2, N=113, Not yet recruiting, Sponsor: Biogen Idec
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 18, 2014
P4, N=100, Completed, Sponsor: Biogen Idec
- Rituxan (rituximab) / Roche
Enrollment closed, Monotherapy: GATEWAY II: Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (clinicaltrials.gov) - May 18, 2014
P2, N=90, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting
- |||| Trimesta (estriol oral) / Synthetic Biologics
Trial completion: A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 14, 2014
P2, N=158, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- fingolimod / Generic mfg.
Clinical: Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya (clinicaltrials.gov) - May 14, 2014
P=N/A, N=20, Recruiting, Sponsor: Stony Brook University
- Enrollment closed, MRI: Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - May 14, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, IO biomarker: Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health (clinicaltrials.gov) - May 14, 2014
P1, N=57, Completed, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed: Dose-finding Study of MT-1303 (clinicaltrials.gov) - May 11, 2014
P2, N=400, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date: Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS (clinicaltrials.gov) - May 11, 2014
P2, N=12, Recruiting, Sponsor: University of Manitoba
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Dec 2014
- Clinical: Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: NHS Greater Glasgow and Clyde
- ||| Tysabri (natalizumab) / Biogen
Clinical: Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri (clinicaltrials.gov) - May 11, 2014
P=N/A, N=400, Enrolling by invitation, Sponsor: Biogen Idec
- ||||| fingolimod / Generic mfg.
New P4 trial: Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) - May 11, 2014
P4, N=400, Recruiting, Sponsor: McGill University
- Trial completion date, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - May 10, 2014
P1, N=400, Recruiting, Sponsor: Carmel Medical Center
Trial primary completion date: Aug 2014 --> Dec 2014 Trial completion date: Oct 2015 --> Dec 2015
- || dalfampridine / Generic mfg.
Trial primary completion date: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - May 8, 2014
P4, N=125, Completed, Sponsor: University of Southern Denmark
Trial completion date: Oct 2015 --> Dec 2015 Trial primary completion date: Dec 2012 --> May 2014
- || dalfampridine / Generic mfg.
Trial completion date: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - May 8, 2014
P4, N=125, Completed, Sponsor: University of Southern Denmark
Trial primary completion date: Dec 2012 --> May 2014 Trial completion date: Dec 2012 --> May 2014
- |||| dalfampridine / Generic mfg.
Trial completion: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - May 8, 2014
P4, N=125, Completed, Sponsor: University of Southern Denmark
Trial completion date: Dec 2012 --> May 2014 Active, not recruiting --> Completed
- Trial primary completion date: Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS (clinicaltrials.gov) - May 8, 2014
P1, N=10, Not yet recruiting, Sponsor: Royan Institute
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Oct 2015
- Trial initiation date: Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS (clinicaltrials.gov) - May 8, 2014
P1, N=10, Not yet recruiting, Sponsor: Royan Institute
Trial primary completion date: Dec 2013 --> Oct 2015 Initiation date: Sep 2012 --> Aug 2014
- Trial completion date: Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS (clinicaltrials.gov) - May 8, 2014
P1, N=10, Not yet recruiting, Sponsor: Royan Institute
Initiation date: Sep 2012 --> Aug 2014 Trial completion date: Dec 2013 --> Nov 2015
- Trial primary completion date: FingoHRV: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P=N/A, N=27, Completed, Sponsor: Kuopio University Hospital
Trial completion date: Dec 2013 --> Nov 2015 Trial primary completion date: Dec 2016 --> Mar 2014
- Trial completion date: FingoHRV: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P=N/A, N=27, Completed, Sponsor: Kuopio University Hospital
Trial primary completion date: Dec 2016 --> Mar 2014 Trial completion date: Dec 2016 --> Mar 2014
- Trial completion: FingoHRV: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P=N/A, N=27, Completed, Sponsor: Kuopio University Hospital
Trial completion date: Dec 2016 --> Mar 2014 Recruiting --> Completed
- Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - May 6, 2014
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Trial primary completion date: Oct 2013 --> Feb 2015
- Trial completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - May 6, 2014
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Oct 2013 --> Feb 2015 Trial completion date: Sep 2014 --> Jul 2015
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date, Metastases: Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma (clinicaltrials.gov) - May 6, 2014
P2, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2014 --> Jul 2015 Trial primary completion date: Oct 2007 --> May 2009
- Zolinza (vorinostat) / Merck (MSD)
Trial completion date, Metastases: Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma (clinicaltrials.gov) - May 6, 2014
P2, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2007 --> May 2009 Trial completion date: Jul 2011 --> May 2009
- Enrollment change: Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P1/2, N=39, Completed, Sponsor: Oregon Health and Science University
Trial completion date: Jul 2011 --> May 2009 N=50 --> 39
- Trial primary completion date: Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - May 6, 2014
P1, N=6, Suspended, Sponsor: TCA Cellular Therapy
N=50 --> 39 Trial primary completion date: Dec 2013 --> May 2014
- Trial suspension: Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - May 6, 2014
P1, N=6, Suspended, Sponsor: TCA Cellular Therapy
Trial primary completion date: Dec 2013 --> May 2014 Active, not recruiting --> Suspended
- Trial completion date: Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - May 6, 2014
P1, N=6, Suspended, Sponsor: TCA Cellular Therapy
Active, not recruiting --> Suspended Trial completion date: Dec 2013 --> May 2014
- | New P1/2 trial: Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P1/2, N=53, Not yet recruiting, Sponsor: Oregon Health and Science University
- |||| Betaseron (IFN-β-1b) / Bayer
Trial completion: BENEFIT 11: Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis (clinicaltrials.gov) - May 4, 2014
P4, N=365, Completed, Sponsor: Bayer
Trial completion date: Dec 2013 --> May 2014 Recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (clinicaltrials.gov) - May 4, 2014
P=N/A, N=30, Recruiting, Sponsor: University of South Florida
Recruiting --> Completed Trial primary completion date: Dec 2013 --> Oct 2014
- Clinical: Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis (clinicaltrials.gov) - May 4, 2014
P=N/A, N=53, Completed, Sponsor: Fondazione Don Carlo Gnocchi Onlus
- Trial primary completion date: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis (clinicaltrials.gov) - May 2, 2014
P=N/A, N=34, Completed, Sponsor: Bert Op't Eijnde
Trial primary completion date: Dec 2013 --> Oct 2014 Trial primary completion date: Aug 2013 --> Mar 2014
- Trial completion date: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis (clinicaltrials.gov) - May 2, 2014
P=N/A, N=34, Completed, Sponsor: Bert Op't Eijnde
Trial primary completion date: Aug 2013 --> Mar 2014 Trial completion date: Nov 2013 --> Mar 2014
- Trial completion: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis (clinicaltrials.gov) - May 2, 2014
P=N/A, N=34, Completed, Sponsor: Bert Op't Eijnde
Trial completion date: Nov 2013 --> Mar 2014 Active, not recruiting --> Completed
- Trial termination: Pennsylvania Consortium: Clinical Database (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=25, Terminated, Sponsor: Drexel University College of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Terminated due to lack of funding and support staff
- Trial termination: Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=107, Terminated, Sponsor: Drexel University College of Medicine
Active, not recruiting --> Terminated; Terminated due to lack of funding and support staff Recruiting --> Terminated; Lack of funding and support staff.
- Enrollment change: Pennsylvania Consortium: Clinical Database (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=25, Terminated, Sponsor: Drexel University College of Medicine
Recruiting --> Terminated; Lack of funding and support staff. N=500 --> 25
- ||| Enrollment closed: Investigation of Sacroiliac Fusion Treatment (INSITE) (clinicaltrials.gov) - Apr 30, 2014
P4, N=200, Active, not recruiting, Sponsor: SI-BONE, Inc.
N=500 --> 25 Recruiting --> Active, not recruiting
- Enrollment change: Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=150, Recruiting, Sponsor: Drexel University College of Medicine
Recruiting --> Active, not recruiting N=90 --> 150
- Trial withdrawal: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Apr 28, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=90 --> 150 Not yet recruiting --> Withdrawn
- Trial initiation date: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Apr 28, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn Initiation date: Dec 2013 --> Jun 2014
- Enrollment change: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Apr 28, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2013 --> Jun 2014 N=132 --> 0
- | Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial termination: DUAL-2: Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (clinicaltrials.gov) - Apr 28, 2014
P3, N=265, Terminated, Sponsor: Actelion
N=132 --> 0 Recruiting --> Terminated; company decision
- ||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial completion: DUAL-1: Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (clinicaltrials.gov) - Apr 28, 2014
P3, N=289, Completed, Sponsor: Actelion
Recruiting --> Terminated; company decision Active, not recruiting --> Completed
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: TOLERATE: Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (clinicaltrials.gov) - Apr 24, 2014
P4, N=230, Not yet recruiting, Sponsor: Biogen Idec
- Enrollment change, Adverse events: Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis (clinicaltrials.gov) - Apr 23, 2014
P1/2, N=22, Completed, Sponsor: Royan Institute
Active, not recruiting --> Completed N=30 --> 22